Novo on Monday released full results from a late-stage trial showing its blockbuster Wegovy injection helped children ages 6 to under 12 with obesity shed weight, significantly lowering their body mass index. Wegovy reduced BMI by an estimated 19.7 percentage points on average compared with a placebo at 68 weeks, with BMI falling 17.4% among children receiving the drug and rising 2.2% among those receiving a placebo. Those results assumed patients stayed on treatment during the trial. When evaluating all children in the study, including those who discontinued treatment, Wegovy lowered BMI by an estimated average of 16.2 percentage points more than the placebo at 68 weeks.
Wir zeigen den wichtigsten Punkt oeffentlich. Erstellen Sie ein kostenloses Konto, um den vollstaendigen Artikel zu lesen, ihn zu speichern, zu diskutieren und mit Markt- und OSINT-Kontext zu verbinden.
